Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) COO Matthew Maxwell Donley Sells 65,902 Shares

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) COO Matthew Maxwell Donley sold 65,902 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $527,216.00. Following the transaction, the chief operating officer now owns 739,456 shares of the company’s stock, valued at $5,915,648. This represents a 8.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Aurinia Pharmaceuticals Stock Performance

AUPH stock opened at $8.08 on Wednesday. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of -53.86 and a beta of 1.22. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.67. The business’s fifty day simple moving average is $8.13 and its two-hundred day simple moving average is $7.85.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. SBI Securities Co. Ltd. purchased a new position in shares of Aurinia Pharmaceuticals during the fourth quarter valued at $25,000. GF Fund Management CO. LTD. bought a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at about $27,000. Tower Research Capital LLC TRC boosted its position in Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC bought a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at about $31,000. Finally, Natixis bought a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at about $49,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 19th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.